Carreira Delgado, Patricia Esmeralda
Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study. [artículo] - Clinical and experimental rheumatology, 2013 - 31(2 Suppl 76):96-102.
Formato Vancouver:
Heijnen IA, Foocharoen C, Bannert B, Carreira PE, Caporali R, Smith V et al. Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study. Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):96-102.
PMID: 23101460
Contiene 34 referencias
OBJECTIVES: To determine the clinical characteristics of simultaneous occurrence of antitopoisomerase (ATA) and anticentromere (ACA) autoantibodies in systemic sclerosis (SSc).
Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study. [artículo] - Clinical and experimental rheumatology, 2013 - 31(2 Suppl 76):96-102.
Formato Vancouver:
Heijnen IA, Foocharoen C, Bannert B, Carreira PE, Caporali R, Smith V et al. Clinical significance of coexisting antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis: a EUSTAR group-based study. Clin Exp Rheumatol. 2013 Mar-Apr;31(2 Suppl 76):96-102.
PMID: 23101460
Contiene 34 referencias
OBJECTIVES: To determine the clinical characteristics of simultaneous occurrence of antitopoisomerase (ATA) and anticentromere (ACA) autoantibodies in systemic sclerosis (SSc).
